imatinib mesylate has been researched along with Hematologic Malignancies in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 27 (57.45) | 29.6817 |
| 2010's | 16 (34.04) | 24.3611 |
| 2020's | 4 (8.51) | 2.80 |
| Authors | Studies |
|---|---|
| Abermil, N; Badaoui, B; Bontoux, C; Crickx, E; Dubois, S; Favre, L; Guermouche, H; Michel, M; Pécriaux, A; Poullot, E; Quang, VT; Roy, L; Sloma, I; Tarfi, S; Wang, L; Xuan, JV | 1 |
| Davare, MA; Druker, BJ; Joshi, SK; Tognon, CE | 1 |
| Cross, NCP; Fabarius, A; Haferlach, T; Hochhaus, A; Hofmann, WK; Jawhar, M; Metzgeroth, G; Naumann, N; Reiter, A; Schwaab, J | 1 |
| Tazi, I | 1 |
| Cascorbi, I; Dworschak, M; Kaehler, M; Liu, C; Nagel, I; Penas, EMM; Rodin, JP; Ruemenapp, J; Vater, I | 1 |
| Ban, H; Hostetler, BJ; McKallip, RJ; Uchakina, ON | 1 |
| Bidet, A; Caillot, D; Chollet, C; Delmer, A; Dulucq, S; Gardembas, M; Genet, P; Lippert, E; Mahon, FX; Nicolini, FE | 1 |
| Baurmann, H; Casper, J; Cross, NCP; Dang, TA; Dietze, L; Döhner, K; Fabarius, A; Haferlach, C; Haferlach, T; Hänel, A; Hochhaus, A; Hofmann, WK; Jawhar, M; Lathan, B; Link, H; Lotfi, S; Maywald, O; Metzgeroth, G; Mielke, S; Müller, L; Naumann, N; Panse, J; Platzbecker, U; Prümmer, O; Reiter, A; Schwaab, J; Thomssen, H; Töpelt, K; Vieler, T | 1 |
| Helbig, G | 1 |
| Flowers, CR; Nastoupil, LJ; Prasad, V | 1 |
| Chantepie, S; Damaj, G; Decamp, M; Henry, A; Hueso, T; Johnson-Ansah, H; Maitre, E; Mensi, S; Vilque, JP | 1 |
| Arpon, DR; Gandhi, MK; Martin, JH | 1 |
| Nishida, T; Tsukazaki, K | 1 |
| Liberante, F; McCabe, B; Mills, KI | 1 |
| Li, KD; Salama, ME | 1 |
| Pop, VP; Rukavitsyn, OA | 1 |
| Bagchi, J; Bandyopadhyay, S; Bhattacharjee, S; Biswas, N; Chaudhuri, U; Ganguly, D; Ghosh, M; Mandal, L; Paul, K; Rakshit, S | 1 |
| Catteau, B; Chevallier, P; Coiteux, V; Jouet, JP; Magro, L; Mohty, M; Terriou, L; Yakoub-Agha, I | 1 |
| Armitage, JO | 1 |
| Adil, SN; Kumar, S; Masood, N | 1 |
| Adachi, S | 1 |
| Kobayashi, Y | 1 |
| Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
| Hoffman, R; Kiladjian, JJ; Mesa, RA | 1 |
| Giannopoulos, K; Kosior, K; Lewandowska-Grygiel, M | 1 |
| Baybay, H; Berrady, R; Bono, W; El Hatimi, A; Gallouj, S; Khammar, Z; Lahlou, M; Lamchachti, L; Mernissi, FZ | 1 |
| Estrov, Z; Ravandi, F; Talpaz, M | 1 |
| Berlanga, J; Büchler, T; Encuentra, M; Ferra, C; Gallardo, D; Grañena, A; Hermosilla, M; Sarra, J | 1 |
| Ford, JM; Hensley, ML | 1 |
| Karp, JE; Lancet, JE | 1 |
| Fujisawa, S; Hatsumi, N; Kishi, K; Miyakoshi, S; Miyawaki, S; Mori, S; Nakajima, H; Oki, M; Sakamaki, H; Sakura, T; Tanaka, Y; Ueyama, J; Yokota, A | 1 |
| Mitani, K | 1 |
| Krause, DS; Van Etten, RA | 1 |
| Akiyama, H; Kanda, Y; Kasai, M; Kato, S; Yamaguchi, H | 1 |
| Bokemeyer, C; Corbin, AS; Deininger, MW; Druker, BJ; Griffith, D; Heinrich, MC; Lee, FY; Schittenhelm, MM; Schroeder, A; Shiraga, S | 1 |
| Boehrer, S; Chow, KU; Hoelzer, D; Mitrou, PS; Nowak, D | 1 |
| Neoh, CY; Ng, SK; Tan, AW | 1 |
| Hayashi, Y | 1 |
| Fujii, S | 1 |
| Atallah, E; Cortes, J; Durand, JB; Kantarjian, H | 1 |
| Yagasaki, F | 1 |
| Baccarani, M; Martinelli, G; Paolini, S; Piccaluga, PP; Rondoni, M; Rosti, G | 1 |
| Avalos, JC; Foncuberta, MC; Tartas, NE | 1 |
| Apperley, J; Corless, CL; Demetri, GD; Di Scala, L; Dirnhofer, S; Fletcher, JA; Harlow, A; Heinrich, MC; Herrmann, R; Joensuu, H; McArthur, AG; McKinley, A; Nikolova, Z; Seymour, J; Soulieres, D; Supple, SG; Town, A; van Oosterom, A | 1 |
| Court, EL; Smith, JG; Smith, MA | 1 |
| Radich, JP | 1 |
26 review(s) available for imatinib mesylate and Hematologic Malignancies
| Article | Year |
|---|---|
Revisiting NTRKs as an emerging oncogene in hematological malignancies.
Topics: Animals; Benzamides; Chromosome Aberrations; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Imatinib Mesylate; Indazoles; Mice; Oncogenes; Point Mutation; Prognosis; Pyrazoles; Pyrimidines; Receptor, trkA; Zebrafish | 2019 |
Imatinib for the treatment of hypereosinophilic syndromes.
Topics: Animals; Antineoplastic Agents; Eosinophils; Hematologic Neoplasms; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction | 2018 |
A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Decision Making; Dose-Response Relationship, Drug; Drug Administration Schedule; Hematologic Neoplasms; Humans; Imatinib Mesylate; Models, Biological; Molecular Targeted Therapy; Piperazines; Precision Medicine; Pyrimidines; Rituximab; Sex Factors | 2014 |
Repurposing medicinal compounds for blood cancer treatment.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Drug Repositioning; Hematologic Neoplasms; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Treatment Outcome | 2015 |
Therapy Effect: Impact on Bone Marrow Morphology.
Topics: Antineoplastic Agents; Atrophy; Bone Marrow; Cytokines; Hematologic Neoplasms; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Lenalidomide; Myeloablative Agonists; Necrosis; Rituximab; Thalidomide | 2016 |
[Limitations in application of imatinib in hematologic malignancies: are there new principal solutions?].
Topics: Antineoplastic Agents; Benzamides; Hematologic Neoplasms; Humans; Imatinib Mesylate; Piperazines; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2008 |
Old disease, new targets. Part-II, haematological malignancies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Drug Costs; Graft vs Host Disease; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Rituximab; Time Factors | 2009 |
[Autophagy in hematologic malignancies].
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Benzamides; Drug Discovery; Hematologic Neoplasms; Humans; Imatinib Mesylate; Membrane Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Molecular target therapy in hematological malignancy: front-runners and prototypes of small molecule and antibody therapy.
Topics: Antibodies, Monoclonal; Antigens, CD20; Benzamides; Biomarkers; Drugs, Investigational; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Follicular; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
The renaissance of interferon therapy for the treatment of myeloid malignancies.
Topics: Apoptosis; Benzamides; Cell Proliferation; Clinical Trials as Topic; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon Type I; Leukemia, Myeloid; Mastocytosis; Neoplastic Stem Cells; Neovascularization, Pathologic; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrimidines; Recombinant Proteins; Thrombocythemia, Essential | 2011 |
Tyrosine kinase inhibitors in hematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
Modulation of cellular signaling pathways: prospects for targeted therapy in hematological malignancies.
Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Drug Design; Hematologic Neoplasms; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Signal Transduction | 2003 |
Outcome and toxicity of salvage treatment on patients relapsing after autologous hematopoietic stem cell transplantation--experience from a single center.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzamides; Disease Progression; Disease-Free Survival; Female; Hematologic Neoplasms; Humans; Imatinib Mesylate; Immunologic Factors; Interferon-gamma; Interleukin-2; Life Tables; Male; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Thalidomide; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2003 |
Imatinib treatment: specific issues related to safety, fertility, and pregnancy.
Topics: Benzamides; Clinical Trials as Topic; Female; Fertility; Hematologic Neoplasms; Humans; Imatinib Mesylate; Male; Piperazines; Pregnancy; Pregnancy Outcome; Pyrimidines | 2003 |
Farnesyl transferase inhibitors in myeloid malignancies.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myeloid, Acute; Models, Biological; Myeloproliferative Disorders; Piperazines; Pyrimidines; Quinolones; ras Proteins; Signal Transduction | 2003 |
[Molecular target therapy for hematologic malignancy].
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gene Targeting; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tretinoin | 2004 |
[Molecular target therapy for malignant tumors].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; ErbB Receptors; Fusion Proteins, bcr-abl; Gefitinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Rituximab; Signal Transduction; Trastuzumab; Tretinoin | 2005 |
Tyrosine kinases as targets for cancer therapy.
Topics: Antibodies, Monoclonal; Benzamides; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Hematologic Neoplasms; Humans; Imatinib Mesylate; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases | 2005 |
[Present status in hematopoietic stem cell transplantation (discussion)].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Benzamides; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Immunosuppressive Agents; Opportunistic Infections; Piperazines; Pyrimidines; Rituximab; Tissue and Organ Procurement; Tissue Donors; Transplantation Conditioning; Transplantation Immunology | 2005 |
Novel agents aiming at specific molecular targets increase chemosensitivity and overcome chemoresistance in hematopoietic malignancies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Oligonucleotides, Antisense; Oxides; Piperazines; Proteasome Endopeptidase Complex; Pyrimidines; Rituximab; Thalidomide | 2006 |
[NKT cell-mediated immunotherapy for hematological malignancies].
Topics: Animals; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Hematologic Neoplasms; Humans; Imatinib Mesylate; Immunity, Innate; Immunotherapy; Killer Cells, Natural; Lymphocyte Activation; Piperazines; Pyrimidines; T-Lymphocyte Subsets | 2007 |
[Tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Benzamides; Hematologic Neoplasms; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Imatinib mesylate in the treatment of hematologic malignancies.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Interactions; Drug Resistance; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Treatment Outcome | 2007 |
[Treatment of hematologic neoplasms during pregnancy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Lymphoma, Non-Hodgkin; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Radiotherapy; Rituximab | 2007 |
Stem cell factor: laboratory and clinical aspects.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Stem Cell Factor | 2001 |
The promise of gene expression analysis in hematopoetic malignancies.
Topics: Animals; Benzamides; DNA Fingerprinting; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines | 2002 |
3 trial(s) available for imatinib mesylate and Hematologic Malignancies
| Article | Year |
|---|---|
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Blast Crisis; Disease-Free Survival; Eosinophilia; Female; Follow-Up Studies; Gene Rearrangement; Hematologic Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Sex Factors; Survival Rate | 2017 |
Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Imatinib Mesylate; Incidence; Leukocyte Transfusion; Life Tables; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2003 |
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
Topics: Antineoplastic Agents; Benzamides; Hematologic Neoplasms; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Mutation; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta | 2008 |
18 other study(ies) available for imatinib mesylate and Hematologic Malignancies
| Article | Year |
|---|---|
[Myeloid neoplasms associated with rearrangement of PDGFRB: A rare and tricky disease].
Topics: Aged; Eosinophilia; Hematologic Neoplasms; Humans; Imatinib Mesylate; Immunoglobulins, Intravenous; In Situ Hybridization, Fluorescence; Male; Myeloproliferative Disorders; Receptor, Platelet-Derived Growth Factor beta | 2022 |
Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation.
Topics: Eosinophilia; Hematologic Neoplasms; Humans; Imatinib Mesylate; Remission Induction; Retrospective Studies; Survival Rate | 2020 |
[Antineoplasic drug repurposing in hematology for COVID-19 treatment].
Topics: Adenine; Aniline Compounds; COVID-19 Drug Treatment; Drug Repositioning; Hematologic Neoplasms; Humans; Imatinib Mesylate; Janus Kinases; Nitriles; Oligopeptides; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinolines | 2021 |
ZFP36L1 plays an ambiguous role in the regulation of cell expansion and negatively regulates CDKN1A in chronic myeloid leukemia cells.
Topics: Adult; Aged; Aged, 80 and over; Butyrate Response Factor 1; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged | 2021 |
Treatment of Hematological Malignancies with Glycyrrhizic Acid.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Glycyrrhizic Acid; Hematologic Neoplasms; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Lymphoma; Mice; Neoplasm Transplantation; Reactive Oxygen Species | 2017 |
Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation.
Topics: Adult; Aged; Antineoplastic Agents; Gene Rearrangement; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Middle Aged; Oncogene Proteins, Fusion; Real-Time Polymerase Chain Reaction | 2018 |
The need to assess financial adverse events.
Topics: Adenine; Child; Costs and Cost Analysis; Hematologic Neoplasms; Humans; Imatinib Mesylate; Piperidines; Pyrazoles; Pyrimidines; Quality of Life; Young Adult | 2018 |
Successful Imatinib therapy as a bridge to transplant in an atypical myeloproliferative neoplasm.
Topics: Amino Acid Substitution; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Isoleucine; Male; Middle Aged; Mutation, Missense; Myeloproliferative Disorders; Neoadjuvant Therapy; Receptors, Colony-Stimulating Factor; Threonine; Transplantation, Homologous; Treatment Outcome | 2019 |
[Inhibitors for ABL, KIT and PDGFR tyrosine kinases--imatinib, nitotinib, and dasatinib].
Topics: Benzamides; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Oncogene Proteins v-abl; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Thiazoles | 2015 |
N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
Topics: Acetylcysteine; Annexin A5; Apoptosis; Benzamides; Cell Line, Tumor; Cell Survival; Free Radical Scavengers; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Nitric Oxide; Nitric Oxide Synthase Type III; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reactive Oxygen Species; Up-Regulation | 2009 |
Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Benzamides; Child, Preschool; Chronic Disease; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Salvage Therapy; Sclerosis; Young Adult | 2009 |
Targeted therapy and hematological malignancy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Benzamides; Biomedical Research; Boronic Acids; Bortezomib; CD52 Antigen; Drug Design; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Glycoproteins; Hematologic Neoplasms; Humans; Imatinib Mesylate; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pulse Therapy, Drug; Pyrazines; Pyrimidines; Rituximab; Survival Rate | 2009 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |
[Acquired ichthyosis and haematological malignancies: five cases].
Topics: Adult; Aged; Allopurinol; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematologic Neoplasms; Hodgkin Disease; Humans; Ichthyosis; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Lung Neoplasms; Lymphoma, B-Cell; Male; Middle Aged; Paraneoplastic Syndromes; Parotid Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prednisone; Procarbazine; Pyrimidines; Retrospective Studies; Rituximab; Schizophrenia; Stomach Neoplasms; Vincristine | 2012 |
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Topics: Amino Acid Substitution; Animals; Benzamides; Cell Growth Processes; Cell Survival; CHO Cells; Cricetinae; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Isoenzymes; MAP Kinase Signaling System; Mice; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; src-Family Kinases; Thiazoles | 2006 |
Sweet's syndrome: a spectrum of unusual clinical presentations and associations.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Drug Eruptions; Female; Hand Dermatoses; Hematologic Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neutrophils; Piperazines; Pyrimidines; Retrospective Studies; Skin Diseases, Vesiculobullous; Sweet Syndrome | 2007 |
[Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biomarkers, Tumor; Child; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Loss of Heterozygosity; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Quinolones; Rituximab; Tretinoin | 2007 |
Congestive heart failure is a rare event in patients receiving imatinib therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Heart Failure; Hematologic Neoplasms; Humans; Imatinib Mesylate; Incidence; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate | 2007 |